//
sign in
Profile
by @danabra.mov
Profile
by @dansshadow.bsky.social
Profile
by @jimpick.com
AviHandle
by @danabra.mov
AviHandle
by @dansshadow.bsky.social
AviHandle
by @katherine.computer
EventsList
by @katherine.computer
ProfileHeader
by @dansshadow.bsky.social
ProfileHeader
by @danabra.mov
ProfileMedia
by @danabra.mov
ProfilePlays
by @danabra.mov
ProfilePosts
by @danabra.mov
ProfilePosts
by @dansshadow.bsky.social
ProfileReplies
by @danabra.mov
Record
by @atsui.org
Skircle
by @danabra.mov
StreamPlacePlaylist
by @katherine.computer
+ new component
ProfilePosts







Great to see my friend and colleague @ldscherer.bsky.social and Kirsten McCaffery from @sydneyhealthlitlab.bsky.social in today's New York Times talking about how calling something "cancer" may not be helpful for decision making about DCIS! Tagging @smdm.bsky.social for amplification.
Jan 30, 2025
Some oncologists suggest that, for certain early cancers not at risk of spreading, the term “cancer” should be avoided.
www.nytimes.com
When ‘Cancer’ Gets in the Way of Treatment
Brian Zikmund-Fisher
🎉 Meet the Member: Brian! 🎉 🧠 Area of Expertise: Risk Communication & Shared Decision-Making 🎭 Fun Fact: Uses improv theater games to enhance teaching, research presentations, and communication skills! Brian has been an SMDM member since 2000 and deeply values its mentoring culture. 💙
Feb 20, 2025
Very proud of authoring this JAMA piece summarizing the most evidence based recommendations we have about communicating probabilities and test results to patients. Now to hope that people believe that using these best practices matters!
8mo
Cannot overstate the importance of this idea: Patients need appropriately selected comparisons in order to understand the meaning of their health data. Great work @ellenpeters.bsky.social !
Great discussion by my colleague @kaytesb.bsky.social on what actually happens to direct-to-consumer genetic testing data.
1mo
Jan 10, 2025
I've published literally hundreds of studies, but this one will always be special. I'm so proud to have helped Dr. Cathryn Lapedis show so convincingly how BAD current prostate biopsy pathology reports are compared to a simple patient-centered design. PLUS: my first JAMA article ever!
Jan 2, 2025
Almost a decade ago, I wrote a piece for TheConversation.com on the (manageable) risks of raw cookie dough (theconversation.com/why-public-h...). It went viral and has something like 400k views. But, the world of dough has changed, so it seemed like a good time for a revision. Enjoy!
Brian Zikmund-Fisher
6mo
The Making Numbers Meaningful Systematic Review papers are now available! Review of 316 papers on communicating health-related probabilities to the public. 1,119 findings. Methods / scoping paper, 6 evidence summary papers, 5 editorials. All open access. journals.sagepub.com/topic/collec...
Brian Zikmund-Fisher
Feb 24, 2025
Brian Zikmund-Fisher
Brian Zikmund-Fisher
Society for Medical Decision Making (SMDM)
Brian Zikmund-Fisher
Public health professor Brian Zikmund-Fisher breaks down the risks from raw eggs and flour in homemade dough—and explains why store-bought "ready to eat" options are now his go-to for satisfying cravi...
sph.umich.edu
Love raw cookie dough? Don’t make it, buy it! | The Pursuit | Risk Communication | Food | Cookie Dough | Health Communication |
Brian Zikmund-Fisher
Clinicians can enhance patient understanding by using numerical data instead of verbal probabilities, consistent denominators, absolute risk comparisons, and clear context for unfamiliar data types. ja.ma/4pAC3zi
8mo
💡 JAMA Insights: Numeric risk comparisons anchored in patient context may improve shared decision-making and help patients interpret clinical choices. ja.ma/42qgUNS
Patient-centered pathology reports improved patients' understanding of prostate biopsy results and their ability to accurately assess their cancer diagnosis and risk level, compared to standard pathology reports. ja.ma/4a3c38z
JAMA
Jan 9, 2025
Jan 2, 2025
1mo
Many who undergo direct-to-consumer genetic testing don’t realize that their data are being licensed to pharmaceutical and biotech companies. JAMA Viewpoint authors @kaytesb.bsky.social and Anya E. R. Prince discuss this gap between consumer expectations and what is being done. ja.ma/40uGL7q
JAMA
JAMA
JAMA